Neurotrope reports positive top-line results from Phase II trial of bryostatin-1 for AD

US-based Neurotrope has reported positive top-line results from the Phase II clinical trial of bryostatin-1 for the treatment of moderate-to-severe Alzheimer's disease (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news